Total submissions: 4
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Molecular Diagnostic Laboratory for Inherited Cardiovascular Disease, |
RCV001256951 | SCV001433482 | uncertain significance | Hypertrophic cardiomyopathy 1 | 2020-02-29 | criteria provided, single submitter | clinical testing | |
Ai |
RCV001781303 | SCV002502096 | likely pathogenic | not provided | 2021-07-20 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV002326683 | SCV002629031 | uncertain significance | Cardiovascular phenotype | 2020-08-26 | criteria provided, single submitter | clinical testing | The p.Y141H variant (also known as c.421T>C), located in coding exon 2 of the JPH2 gene, results from a T to C substitution at nucleotide position 421. This variant was reported in one sporadic hypertrophic cardiomyopathy (HCM) case, and functional studies indicate that this alteration may impact protein function (Landstrom AP et al. J. Mol. Cell. Cardiol., 2007 Jun;42:1026-35; Woo JS et al. J. Biol. Chem., 2012 Apr;287:14336-48). The tyrosine at codon 141 is replaced by histidine, an amino acid with similar properties. This amino acid position is highly conserved in available vertebrate species. In addition, the in silico prediction for this alteration is inconclusive. Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear. |
OMIM | RCV000023409 | SCV000044700 | pathogenic | Hypertrophic cardiomyopathy 17 | 2007-06-01 | no assertion criteria provided | literature only |